Home Tags SALCL

Tag: sALCL

Long-Term Data Continues to Support Development Strategy to Establish Brentuximab Vedotin...

Final data from the pivotal phase II trial with brentuximab vedotin (Adcetris®; Seattle Genetics/Takada)   in relapsed* or refractory** (r/r) systemic anaplastic large cell lymphoma (sALCL)...

Commercial and Regulatory Progress under Brentuximab Vedotin Collaboration Between Seattle Genetics...

Nearly 7 years ago, in 2009, Seattle Genetics, a clinical stage biopharmaceutical company, and Takeda Pharmaceuticals, Japan's largest pharmaceutical company with a 230+ year...

European Commission Approves Label Variation for Brentuximab Vedotin

The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to include data on the...

Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...

Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy.  Oral...

Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...

Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...

Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...

Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...

Updated Data for Brentuximab Vedotin Shows Durable Complete Remission and Manageable...

Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)...

FEATURED RESOURCES